Thyrocare Technologies reported a strong Q4 FY ’26, with consolidated revenue growing 20% year-on-year. The company achieved a 34% EBITDA margin and a 128% surge in PAT, reaching INR 48.7 crores. Key drivers included robust growth in its flagship Aarogyam and Jaanch brands, strategic franchise expansion to 10,800 active franchisees, and a significant 23% year-on-year growth in total test volumes during the fiscal year.
Financial Performance Highlights
For the full financial year FY ’26, Thyrocare achieved consolidated revenue of INR 829 crores, reflecting a strong 21% growth over the previous year. Profitability also saw substantial gains, with EBITDA reaching INR 262 crores and Profit After Tax (PAT) at INR 163 crores, marking an 81% growth year-on-year. The company’s earnings per share (adjusted for bonus issues) climbed to INR 2.99, up 64% from the previous year.
Operational Expansion and Scale
Thyrocare continues to build its operational backbone to support long-term growth. The company successfully processed 210 million tests in FY ’26, serving 19.2 million patients, a 15% increase. The lab network now encompasses 40 laboratories across India and one in Tanzania. Operational efficiency remains a priority, with the company maintaining a Six Sigma level of performance, achieving an average turnaround time of 3.43 hours per sample in Q4 FY ’26.
Strategic Initiatives and Specialty Focus
The company is aggressively entering the specialty diagnostics space, including genomics, allergy testing, and histopathology. Management aims to build this into a significant growth pillar, projecting it could reach 15% to 20% of the total diagnostic mix within three years. By leveraging a high-volume franchise network and maintaining a disruptive pricing strategy, Thyrocare intends to democratize access to advanced diagnostic testing.
Outlook for FY ’27
Looking ahead, Thyrocare remains committed to its core B2B strategy while focusing on volume-led growth. The company anticipates maintaining EBITDA margins in the 33% to 34% range while continuing to invest in technology and expansion. Management has indicated that while specialty segments are currently in a nascent stage, they are positioned to drive significant value over the 3-year horizon through increased test menus and deeper engagement with medical professionals.
Source: BSE
